UCB (OTCMKTS:UCBJY) Shares Gap Down – Here’s What Happened

UCB SA (OTCMKTS:UCBJY) gapped down before the market opened on Thursday . The stock had previously closed at $142.88, but opened at $124.64. UCB shares last traded at $123.53, with a volume of 4,924 shares changing hands.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Zacks Research raised UCB from a “strong sell” rating to a “hold” rating in a research note on Monday, July 6th. Barclays downgraded UCB from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 15th. Finally, Jefferies Financial Group upgraded UCB to a “moderate sell” rating in a research report on Monday, June 22nd. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold”.

UCB Trading Down 13.1%

The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.04 and a current ratio of 1.38. The business has a 50 day moving average price of $144.07 and a 200 day moving average price of $147.71.

UCB Company Profile

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.